NEW SILKROAD (00472) issues a profit warning, expecting a mid-term net loss attributable to shareholders to narrow to approximately HKD 13 million to 17 million compared to the same period last year.

17:59 12/08/2026

New Silkroad Culturaltainment Holdings Group (00472) announced that, based on the Group's preliminary review of the unaudited consolidated management accounts for the six months ending June 30, 2026 (the "Period"), the Group anticipates a reduction in the net loss attributable to the owners of the Company, amounting to approximately HKD 13.9 million to HKD 17 million, while the net loss for the same period in 2025 was approximately HKD 41.7 million. This is mainly attributed to a decrease in impairment losses on goodwill. The impairment losses are a non-cash item and are expected not to adversely affect the Group's operating cash flow or business operations.

NEW SILKROAD (00472) announced that, based on the Group's preliminary review of the unaudited consolidated management accounts for the six months ending June 30, 2026 (the "period"), the Group expects to record a reduction in net loss attributable to shareholders of the Company, amounting to approximately HK$13.9 million to HK$17 million, compared to a net loss of approximately HK$41.7 million for the same period in 2025. This change is mainly due to a decrease in goodwill impairment loss. The impairment loss is a non-cash item and is expected to have no adverse impact on the Group's operating cash flow or business operations.

ORIENTAL EXPL (00430) issues a profit warning, expecting that integrated profit attributable to shareholders for the first half of the year will decrease to approximately HK$3 million to HK$3.2 million.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.